Autoimmune Disease Therapeutics: A Global Strategic Business Report
San Jose, CA (PRWEB) June 30, 2009
Global market for Autoimmune Disease Therapeutics is projected to reach US$49.8 billion in 2015. Biologics emerged as the leading therapeutic option in the treatment of autoimmune diseases, owing to their superior efficacy compared to conventional small molecule drugs. Fueling growth are factors such as introduction of new products, enhanced access to drugs, and enhanced penetration of existing drugs. Access to biologics in the world's largest drug market, the US, is due primarily to the inclusion of Humira and Enbrel into Medicare Part D reimbursement in early 2006. New products that are being launched in the market provide expanded therapeutic options for patients who fail to respond to existing therapies. The United States represents the largest market for biological autoimmune disease therapeutics, while Europe represents the fastest growing market worldwide. Rheumatoid Arthritis represents the largest segment in the global market, while Crohn's Disease represents the fastest growing segment for biologics in the global autoimmune disease therapeutics market.
Lack of awareness on the disease and associated symptoms curbed accurate diagnosis of autoimmune diseases in the past. Symptoms of most autoimmune diseases are similar to that of certain common conditions that lead to wrong diagnoses, and consequently raise healthcare costs. Rapid advancement in the area of disease diagnostics is increasingly enabling physicians in making accurate diagnosis of various autoimmune diseases, which is resulting in a rise in number of patients diagnosed, and subsequently higher number of patients receiving therapy. Leading biological drugs in the present day treatment of autoimmune diseases include TNF inhibitors, such as Enbrel, Humira and Remicade. New products in the market, such as Rituxan and Orencia made significant inroads by addressing therapeutic needs not addressed by existing drugs.
The global marketplace is characterized by participants such as Abbott Laboratories, Amgen Inc., Bayer Schering Pharma AG, Biogen Idec Inc., Bristol-Myers Squibb Company, Chugai Pharmaceutical Co., Ltd., Elan Corporation, plc, Eli Lilly And Company, F. Hoffmann-La Roche AG, Genentech, Inc., GlaxoSmithKline plc, Johnson & Johnson, Inc., Merck Serono SA, Novartis AG, sanofi-aventis SA, Schering-Plough Corporation, Shire Pharmaceuticals Group plc., Teva Pharmaceuticals Industries Limited, UCB Pharma.
"Autoimmune Disease Therapeutics: A Global Strategic Business Report" announced by Global Industry Analysts, Inc. provides a comprehensive review of market trends, drivers, product profile, players, competition, recent developments, mergers, acquisitions, and other strategic industry activities. Analysis is presented for major geographic markets such as the US, Japan, Europe and Rest of World. Global and regional analytics are provided for product segments such as Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Crohn's Disease and Other Autoimmune Diseases.
For more details about this comprehensive market research report, please visit - http://www.strategyr.com/Autoimmune_Disease_Therapeutics_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Email press (at) StrategyR (dot) com
Web Site http://www.StrategyR.com/